Published in Am J Hematol on March 01, 1995
Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med (1985) 8.16
Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA (1999) 7.37
Production of collagenase and prostaglandins by isolated adherent rheumatoid synovial cells. Proc Natl Acad Sci U S A (1976) 5.40
Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin 1). Proc Natl Acad Sci U S A (1981) 4.89
Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med (1999) 4.79
Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med (1988) 4.69
Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum (1990) 4.39
CCR5 is characteristic of Th1 lymphocytes. Nature (1998) 3.92
Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum (1995) 3.83
Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. J Clin Invest (1986) 3.43
Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry (2002) 3.41
Participation of monocyte-macrophages and lymphocytes in the production of a factor that stimulates collagenase and prostaglandin release by rheumatoid synovial cells. J Clin Invest (1979) 3.34
Collagenase production by rheumatoid synovial cells: stimulation by a human lymphocyte factor. Science (1977) 2.91
Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology (2006) 2.90
Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages. J Exp Med (1984) 2.78
Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J Infect Dis (1987) 2.71
Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis (2000) 2.59
Prediction of malignant middle cerebral artery infarction by diffusion-weighted imaging. Stroke (2000) 2.59
Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology (2007) 2.52
Prostaglandin production by rheumatoid synovial cells: stimulation by a factor from human mononuclear Cells. J Exp Med (1977) 2.47
Purification of a factor from human blood monocyte-macrophages which stimulates the production of collagenase and prostaglandin E2 by cells cultured from rheumatoid synovial tissues. FEBS Lett (1981) 2.27
Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance. J Neurosurg (2000) 2.25
A urine inhibitor of interleukin 1 activity that blocks ligand binding. J Immunol (1987) 2.17
Cloning and analysis of the K1 capsule biosynthesis genes of Escherichia coli: lack of homology with Neisseria meningitidis group B DNA sequences. Infect Immun (1983) 2.15
Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine (2000) 2.11
Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry (2005) 2.08
Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chem (1989) 2.07
High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis (1992) 2.05
Relation between tumor necrosis factor-alpha and granulocyte elastase-alpha 1-proteinase inhibitor complexes in the plasma of patients with cystic fibrosis. Am Rev Respir Dis (1989) 1.99
Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol (2004) 1.97
Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol (1998) 1.97
Purification and characterization of human interleukin-1 beta expressed in recombinant Escherichia coli. Eur J Biochem (1986) 1.89
Ehlers-Danlos syndrome type IV: a multi-exon deletion in one of the two COL3A1 alleles affecting structure, stability, and processing of type III procollagen. J Biol Chem (1988) 1.88
A human inhibitor of tumor necrosis factor alpha. J Exp Med (1988) 1.85
Increased prostaglandin production by human monocytes after membrane receptor activation. J Immunol (1979) 1.77
Synthesis of interleukin 1/endogenous pyrogen in the brain of endotoxin-treated mice: a step in fever induction? J Immunol (1984) 1.71
Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). J Clin Invest (1986) 1.70
Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol (1998) 1.70
Interleukin 1 is present in normal human epidermis. J Immunol (1986) 1.70
Pallidal stimulation for Parkinson's disease. Two targets? Neurology (1997) 1.69
IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest (1995) 1.69
Induction of human interleukin 1 mRNA measured by collagenase- and prostaglandin E2-stimulating activity in rheumatoid synovial cells. Eur J Immunol (1984) 1.66
Purified blood monocytes from HIV 1-infected patients produce high levels of TNF alpha and IL-1. Clin Immunol Immunopathol (1989) 1.63
IFN-gamma and 1,25(OH)2D3 induce on THP-1 cells distinct patterns of cell surface antigen expression, cytokine production, and responsiveness to contact with activated T cells. J Immunol (1992) 1.62
Tourette's syndrome and deep brain stimulation. J Neurol Neurosurg Psychiatry (2005) 1.60
Crucial role of tumor necrosis factor (TNF) receptor 2 and membrane-bound TNF in experimental cerebral malaria. Eur J Immunol (1997) 1.56
Failure of long-term pallidal stimulation corrected by subthalamic stimulation in PD. Neurology (2000) 1.55
Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production. J Immunol (1990) 1.48
Brainstem gliomas in adults: prognostic factors and classification. Brain (2001) 1.46
Immunomodulation by intravenous immunoglobulin. Am J Pediatr Hematol Oncol (1990) 1.46
Macrophage inflammatory protein-1: a prostaglandin-independent endogenous pyrogen. Science (1989) 1.46
Cytokines and other mediators in rheumatoid arthritis. Springer Semin Immunopathol (1984) 1.45
A urine inhibitor of interleukin 1 activity affects both interleukin 1 alpha and 1 beta but not tumor necrosis factor alpha. J Immunol (1987) 1.44
[Cerebral tropical malaria with blackwater fever. A current diagnostic and therapeutic problem]. Schweiz Med Wochenschr (1974) 1.41
Amoxycillin/clavulanic acid prophylaxis in elective colorectal surgery: a prospective randomized trial. J Hosp Infect (1997) 1.39
Clinical predictive factors of subthalamic stimulation in Parkinson's disease. Brain (2002) 1.38
Suppression of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4. J Clin Invest (1992) 1.38
Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. J Biol Chem (1994) 1.36
Correspondence between functional magnetic resonance imaging somatotopy and individual brain anatomy of the central region: comparison with intraoperative stimulation in patients with brain tumors. J Neurosurg (2000) 1.35
Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol (1997) 1.32
Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor. Proc Natl Acad Sci U S A (1990) 1.30
Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinases 1 in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes: involvement of membrane-associated cytokines. Arthritis Rheum (1998) 1.30
Limited effects of recombinant human and murine interleukin 1 and tumour necrosis factor on production of acute phase proteins by cultured rat hepatocytes. Biochem Int (1987) 1.30
The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis. Arthritis Rheum (2000) 1.29
Matrix metalloproteinases and TIMP in acute respiratory distress syndrome. Am J Respir Crit Care Med (1996) 1.29
Purification and characterization of human interleukin-1 alpha produced in Escherichia coli. Eur J Biochem (1987) 1.28
Aggressive behavior induced by intraoperative stimulation in the triangle of Sano. Neurology (2002) 1.27
Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: a possible role of CD69. Eur Cytokine Netw (1993) 1.26
Killing of Staphylococcus aureus by tumor necrosis factor-alpha-activated neutrophils. The role of serum opsonins, integrin receptors, respiratory burst, and degranulation. J Immunol (1993) 1.25
Interactions among rheumatoid synovial cells and monocyte-macrophages: production of collagenase-stimulating factor by human monocytes exposed to concanavalin A or immunoglobulin Fc fragments. J Immunol (1980) 1.24
The functional importance of a cap site-proximal region of the human prointerleukin 1 beta gene is defined by viral protein trans-activation. Mol Cell Biol (1992) 1.24
Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur Cytokine Netw (1997) 1.23
Mononuclear cell-conditioned medium containing mononuclear cell factor (MCF), homologous with interleukin 1, stimulates collagen and fibronectin synthesis by adherent rheumatoid synovial cells: effects of prostaglandin E2 and indomethacin. Coll Relat Res (1985) 1.22
Axial parkinsonian symptoms can be improved: the role of levodopa and bilateral subthalamic stimulation. J Neurol Neurosurg Psychiatry (2000) 1.21
Localization of [3H]ouabain-sensitive Na+ pump sites in cultured pig kidney cells. Am J Physiol (1979) 1.19
Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis. Lancet (1987) 1.19
Human Th1 cells preferentially induce interleukin (IL)-1beta while Th2 cells induce IL-1 receptor antagonist production upon cell/cell contact with monocytes. Eur J Immunol (1997) 1.18
Procalcitonin, IL-6, IL-8, IL-1 receptor antagonist and C-reactive protein as identificators of serious bacterial infections in children with fever without localising signs. Eur J Pediatr (2001) 1.18
EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force. Eur J Neurol (2006) 1.17
PET study of carbon-11-PK 11195 binding to peripheral type benzodiazepine sites in glioblastoma: a case report. J Nucl Med (1991) 1.17
Modulation of endotoxic activity of lipopolysaccharide by high-density lipoprotein. Pathobiology (1991) 1.17
Treatment of severe aplastic anaemia with antilymphocyte globulin or bone-marrow transplantation. Br Med J (Clin Res Ed) (1981) 1.16
Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. The J5 Study Group. Immunology (1992) 1.16
The insulin receptor of a human monocyte-like cell line: characterization and function. Endocrinology (1984) 1.16
Subthalamic stimulation in Parkinson disease: a multidisciplinary approach. Arch Neurol (2000) 1.15
Production of monoclonal antibodies against interleukin-1 alpha and -1 beta. Development of two enzyme immunometric assays (EIA) using acetylcholinesterase and their application to biological media. J Immunol Methods (1989) 1.15
The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest (1995) 1.15
Rheumatoid synovial cell morphologic changes induced by a mononuclear cell factor in culture. Arthritis Rheum (1983) 1.14
Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study. Rheumatology (Oxford) (2001) 1.14
A cell strain cultured from porcine kidney increases cyclic AMP content upon exposure to calcitonin or vasopressin. Biochem Biophys Res Commun (1978) 1.14
Induction of plasma inhibitors of interleukin 1 and TNF-alpha activity by endotoxin administration to normal humans. Am J Physiol (1990) 1.14
Correlations between molecular profile and radiologic pattern in oligodendroglial tumors. Neurology (2004) 1.14
Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol (1997) 1.13
Inhibition by retinoic acid of collagenase production in rheumatoid synovial cells. N Engl J Med (1980) 1.12
Spondyloepiphyseal dysplasia, corneal clouding, normal intelligence and acid beta-galactosidase deficiency. Clin Genet (1976) 1.12
Platelet function in congenital afibrinogenemia. Thromb Diath Haemorrh (1965) 1.12
Successful treatment of polyarteritis nodosa related to hepatitis B virus with a combination of lamivudine and interferon alpha. Rheumatology (Oxford) (1999) 1.12